RTI-371

Chemical compound
RTI-371
Identifiers
  • 3-(4-Chlorophenyl)-5-[(1R,2S,3S,5S)-8-methyl-3-(4-methylphenyl)-8-azabicyclo[3.2.1]octan-2-yl]-1,2-oxazole
CAS Number
  • 652978-45-5 ☒N
PubChem CID
  • 11474847
Chemical and physical data
FormulaC24H25ClN2O
Molar mass392.93 g·mol−1
3D model (JSmol)
  • Interactive image
  • CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=CC(=NO4)C5=CC=C(C=C5)Cl)N3C
 ☒NcheckY (what is this?)  (verify)

3β-(4-Methylphenyl)-2β-[3-(4-chlorophenyl)isoxazol-5-yl]tropane (RTI-4229-371) is a phenyltropane derived drug which acts as a potent and selective dopamine reuptake inhibitor in vitro, yet unusually for this class of compound, both RTI-371 and the closely related compound RTI-370 failed to produce locomotor stimulation in mice. In addition to this, in drug substitution tests RTI-370 weakly generalized to cocaine whereas RTI-371 did not generalize at all.

This phenomenon has also been observed for other dopamine reuptake inhibitors from other classes. It may be caused by lack of BBB penetration, or interactions at alternative receptor sites.[1][2]

See also

References

  1. ^ Navarro HA, Howard JL, Pollard GT, Carroll FI (April 2009). "Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter". British Journal of Pharmacology. 156 (7): 1178–84. doi:10.1111/j.1476-5381.2009.00124.x. PMC 2697692. PMID 19226282.
  2. ^ Foster MD (2011). Computational study of RTI-371, a positive allosteric modulator of the cannabinoid CB1 receptor (PDF) (MSc thesis). The University of North Carolina at Greensboro.
  • v
  • t
  • e
Phenyltropanes (classifications)
2-Carboxymethyl Esters
(3,4-Disubstituted Phenyl)-tropanesArylcarboxyCarboxyalkylAcyl
  • PTT/WF-11
  • WF-23
  • PIT/WF-21
  • WF-33
β,α Stereochemistryα,β StereochemistryHeterocycles: 3-Substituted-isoxazol-5-yl
Heterocycles: 3-Substituted-1,2,4-oxadiazole
N-alkyl
  • FP-β-CPPIT
  • FE-β-CPPIT
  • Altropane
  • Ioflupane (123I)
N-replaced (S,O,C)IrreversibleNortropanes (N-demethylated)
  • v
  • t
  • e
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Pyrrolidines
Racetams
Tropanes
Tryptamines
Others
  • v
  • t
  • e
Receptor
(ligands)
CB1Tooltip Cannabinoid receptor type 1
Agonists
(abridged,
full list)
Inverse agonists
Antagonists
CB2Tooltip Cannabinoid receptor type 2
Agonists
Antagonists
NAGly
(GPR18)
Agonists
Antagonists
GPR55
Agonists
Antagonists
GPR119
Agonists
Transporter
(modulators)
eCBTsTooltip Endocannabinoid transporter
Enzyme
(modulators)
FAAHTooltip Fatty acid amide hydrolase
  • Activators: PDP-EA
MAGL
ABHD6
  • Inhibitors: JZP-169
  • JZP-430
  • KT182
  • KT185
  • KT195
  • KT203
  • LEI-106
  • ML294
  • ML295
  • ML296
  • UCM710
  • WWL-70
ABHD12
Others
  • Others: 2-PG (directly potentiates activity of 2-AG at CB1 receptor)
  • ARN-272 (FAAH-like anandamide transporter inhibitor)
See also
Receptor/signaling modulators
Cannabinoids (cannabinoids by structure)
  • v
  • t
  • e
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
  • See also: Receptor/signaling modulators
  • Adrenergics
  • Serotonergics
  • Monoamine reuptake inhibitors
  • Monoamine releasing agents
  • Monoamine metabolism modulators
  • Monoamine neurotoxins